Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients
- 29 December 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (8) , 3105-3114
Abstract
Aims: Ganciclovir (GCV) and its prodrug valganciclovir (VGCV) are first‐line agents to prevent and treat cytomegalovirus in transplant recipients. There is high pharmacokinetic (PK) interindividual variability and PK data are scarce, especially in paediatric stem cell transplant (SCT) recipients. We sought to determine the optimal GCV and VGCV dosing in transplanted children.Methods: We conducted a single‐centre retrospective population PK (POPPK) study of IV GCV and enteral VGCV in paediatric solid organ transplant (SOT) and SCT recipients. We included children who were transplanted and had available plasma GCV concentrations, done per standard of care. POPPK analysis was performed using a nonlinear mixed effects modelling approach with NONMEM. Optimal dosing was determined based on the achievement of the surrogate efficacy target: GCV 24 h area under the concentration–time curve (AUC0‐24h) of 40–60 mg.h.L−1.Results: Fifty children with a median [range] age of 7.5 years [0.5–17.4] contributed 580 PK samples. A two‐compartment model with first‐order absorption with a lag time and first‐order elimination fit the data well. Creatinine clearance and body weight (WT) were significant covariates for GCV clearance (CL); and WT for the volumes of distribution. IV GCV 15–20 mg.kg−1.day−1 divided every 12 hours achieved the highest probability of target achievement (PTA) (33.0–33.8%). Enteral VGCV 30 and 40 mg.kg−1.day−1 divided every 12 hours in children 0–<6 years, and 6–18 years, respectively, achieved the highest PTA (29.1–33.0%).Conclusion: This is the first POPPK model developed in children with either SOT or SCT. Concentration target achievement was low, suggesting a potential benefit for therapeutic drug monitoring to ensure optimal exposure.Keywords
This publication has 37 references indexed in Scilit:
- Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipientsPediatric Transplantation, 2012
- Pharmacokinetic Profile of Valganciclovir in Pediatric Transplant RecipientsThe Pediatric Infectious Disease Journal, 2012
- Population Pharmacokinetics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in Solid Organ Transplant Patients Infected with CytomegalovirusAntimicrobial Agents and Chemotherapy, 2009
- How we treat cytomegalovirus in hematopoietic cell transplant recipientsBlood, 2009
- Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant PatientsClinical Pharmacokinetics, 2009
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Pharmacokinetics of ganciclovir in pediatric renal transplant recipientsPediatric Nephrology, 2003
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976